Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro

To identify drugs that are potentially used for the treatment of COVID-19, the potency of 1403 FDA-approved drugs were evaluated using a robust pseudovirus assay and the candidates were further confirmed by authentic SARS-CoV-2 assay. Four compounds, Clomiphene (citrate), Vortioxetine, Vortioxetine...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 11; p. 609592
Main Authors Xiong, Hua-Long, Cao, Jia-Li, Shen, Chen-Guang, Ma, Jian, Qiao, Xiao-Yang, Shi, Tian-Shu, Ge, Sheng-Xiang, Ye, Hui-Ming, Zhang, Jun, Yuan, Quan, Zhang, Tian-Ying, Xia, Ning-Shao
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 05.02.2021
Subjects
drug combination
drug screening
Pharmacology
pseudovirus assay
SARS-CoV-2
vesicular stomatitis virus
SARS-CoV-2
pseudovirus assay
drug screening
drug combination
vesicular stomatitis virus
Online AccessGet full text

Cover

More Information
Summary:To identify drugs that are potentially used for the treatment of COVID-19, the potency of 1403 FDA-approved drugs were evaluated using a robust pseudovirus assay and the candidates were further confirmed by authentic SARS-CoV-2 assay. Four compounds, Clomiphene (citrate), Vortioxetine, Vortioxetine (hydrobromide) and Asenapine (hydrochloride), showed potent inhibitory effects in both pseudovirus and authentic virus assay. The combination of Clomiphene (citrate), Vortioxetine and Asenapine (hydrochloride) is much more potent than used alone, with IC50 of 0.34 μM.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Xuping Xie, University of Texas Medical Branch at Galveston, United States
This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology
These authors have contributed equally to this work
Edited by: Rafael Maldonado, Pompeu Fabra University, Spain
Silvia Spoto, Policlinico Universitario Campus Bio-Medico, Italy
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2020.609592